Trial Profile
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Dusigitumab (Primary) ; Anastrozole; Exemestane; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 31 Jul 2018 Planned End Date changed from 8 Jun 2018 to 5 Jun 2020.
- 26 Jan 2018 Planned End Date changed from 27 Oct 2017 to 8 Jun 2018.